The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy
Abstract
Purpose: Pathologic complete remission (pCR) of primary breast tumors after primary chemotherapy (PCT) is associated with higher relapse-free survival (RFS) and overall survival (OS) rates. The purpose of this study was to determine long-term outcome in patients achieving pCR of cytologically proven axillary lymph node (ALN) metastases. Methods: Patients with cytologically documented ALN metastases were treated in five prospective PCT trials. After surgery, patients were subdivided into those with and without residual ALN carcinoma. Survival was calculated by the Kaplan-Meier method. Results: Of 925 patients treated, 403 patients had cytologically confirmed ALN metastases. Eighty-nine patients (22%) achieved ALN pCR after PCT. Compared with the group without ALN pCR, 5-year OS and RFS were improved in patients achieving ALN pCR (93% [95% CI, 87.5 to 98.5] and 87% [95% CI, 79.7 to 94.3] v 72% [95% CI, 66.5 to 77.5] and 60% [95% CI, 54.1 to 65.9], respectively; P < .0001). Residual primary tumor did not affect outcome of those with ALN pCR. Combination anthracycline/taxane-based PCT resulted in significantly more ALN pCRs, although outcome after ALN pCR was not improved by taxanes. We constructed a nomogram demonstrating that patients who do not benefit from neoadjuvant anthracyclines are unlikely to benefit from subsequent taxanes. Conclusion: ALN pCR is associated with an excellent prognosis, even with a residual primary tumor, pointing to biologic differences between primary and metastatic cells. ALN pCR represents an early surrogate marker of long-term outcome. Response to initial PCT has important potential as a guide to subsequent therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Hsu, S. M., Raine, L., & Fanger, H. (1981) · Journal of Histochemistry & Cytochemistry · doi:10.1177/29.4.6166661 · Cited by 14,140
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330
Self-citationBear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.005 · Cited by 1,118
Chang, J. C., Wooten, E. C., Tsimelzon, A., Hilsenbeck, S. G., Gutierrez, M. C., Elledge, R., Mohsin, S., Osborne, C. K., Chamness, G. C., Allred, D. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14023-8 · Cited by 875
Gianni, L., Zambetti, M., Clark, K., Baker, J., Cronin, M., Wu, J., Mariani, G., Rodriguez, J., Carcangiu, M., Watson, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0818 · Cited by 626
Self-citationAyers, M., Symmans, W. F., Stec, J., Damokosh, A. I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.166 · Cited by 566
Self-citationScholl, S. M., Fourquet, A., Asselain, B., Pierga, J. Y., Vilcoq, J. R., Durand, J. C., Dorval, T., Palangié, T., Jouve, M., Beuzeboc, P., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90537-1 · Cited by 424
Fisher, E. R., Wang, J., Bryant, J., Fisher, B., Mamounas, E., & Wolmark, N. (2002) · Cancer · doi:10.1002/cncr.10741 · Cited by 413
Kuerer, H. M., Sahin, A. A., Hunt, K. K., Newman, L. A., Breslin, T. M., Ames, F. C., Ross, M. I., Buzdar, A. U., Hortobagyi, G. N., & Singletary, S. E. (1999) · Annals of Surgery · doi:10.1097/00000658-199907000-00011 · Cited by 357
Self-citationRouzier, R., Extra, J.-M., Klijanienko, J., Falcou, M.-C., Asselain, B. J. R., Vincent‐Salomon, A., Vielh, P. R., & Bourstyn, E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1304 · Cited by 315
Self-citationBacci, G., Picci, P., Ferrari, S., Ruggieri, P., Casadei, R., Tienghi, A., Prever, A. B. D., Gherlinzoni, F., Mercuri, M., & Monti, C. (1993) · Cancer · doi:10.1002/1097-0142(19931201)72:11<3227::aid-cncr2820721116>3.0.co;2-c · Cited by 294
Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer
De Lena, M., Zucali, R., Viganotti, G., Valagussa, P., & Bonadonna, G. (1978) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00253147 · Cited by 272
Martincich, L., Montemurro, F., De Rosa, G., Marra, V., Ponzone, R., Cirillo, S., Gatti, M., Biglia, N., Sarotto, I., Sismondi, P., et al. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000010700.11092.f4 · Cited by 240
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.
Herr, H. W., Bajorin, D. F., & Scher, H. I. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1298 · Cited by 203
Results of cancer and leukemia group B protocol 8935
Sugarbaker, D. J., Herndon, J., Kohman, L. J., Krasna, M. J., & Green, M. R. (1995) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(95)70278-4 · Cited by 187
Kuerer, H. M., Newman, L. A., Buzdar, A. U., Hunt, K. K., Dhingra, K., Buchholz, T. A., Binkley, S. M., Ames, F. C., Feig, B. W., Ross, M. I., et al. (1998) · The American Journal of Surgery · doi:10.1016/s0002-9610(98)00253-0 · Cited by 152
Self-citationFDG-PET in monitoring therapy of breast cancer
Biersack, H. J., Bender, H., & PALMEDO, H. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1533-x · Cited by 49
Phase I trials of dexrazoxane and other potential applications for the agent.
Hoff, D. D. V. (1998) · PubMed · Cited by 36
Cited by
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Self-citationBoughey, J. C. (2013) · JAMA · doi:10.1001/jama.2013.278932 · Cited by 1,588
Boughey, J. C., McCall, L. M., Ballman, K. V., Mittendorf, E. A., Ahrendt, G. M., Wilke, L. G., Taback, B., Leitch, A. M., Flippo-Morton, T., & Hunt, K. K. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000924 · Cited by 440
Kaufmann, M., von Minckwitz, G., Bear, H. D., Buzdar, A., McGale, P., Bonnefoi, H., Colleoni, M., Denkert, C., Eiermann, W., Jackesz, R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm201 · Cited by 386
Self-citationPierga, J.-Y., Bidard, F.-C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., de Cremoux, P., Salmon, R., Vincent-Salomon, A., & Marty, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0030 · Cited by 369
Metadata
- Authors
- Hennessy, B. T., Hortobagyi, G. N., Rouzier, R., Kuerer, H., Sneige, N., Buzdar, A. U., Kau, S. W., Fornage, B., Sahin, A., Broglio, K., Singletary, S. E., & Valero, V.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-20
- Volume
- 23
- Issue
- 36
- Pages
- 9304-9311
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2138902655
- Cited by
- 420
- References
- 22
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.